top of page

The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset

Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an update on Amylyx's existing pipeline, including recent data in Wolfram Syndrome.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

bottom of page